<DOC>
	<DOCNO>NCT02279992</DOCNO>
	<brief_summary>This randomize pilot study investigate ability phosphodiesterase-V inhibitor ( vardenafil ) increase concentration systemically deliver chemotherapy , carboplatin , patient recurrent malignant glioma metastatic brain cancer . This study also determine toxicity tolerability phosphodiesterase-V inhibitor ( vardenafil ) combination intravenous carboplatin patient recurrent malignant glioma metastatic brain cancer .</brief_summary>
	<brief_title>Pilot Study Vardenafil Carboplatin Patients With Gliomas Brain Metastases</brief_title>
	<detailed_description>Twenty patient ( 10 pt recurrent malignant glioma 10 pt metastatic brain tumor ) randomly assign receive either phosphodiesterase-V inhibitor ( vardenafil ) follow carboplatin carboplatin alone . All patient tumor resection perform 2 6 hour administration carboplatin . Using high performance liquid chromatographic ( HPLC ) ELISA methodology , carboplatin level determine serum resect tumor tissue . Patients follow four week craniotomy toxicity associate administration carboplatin phosphodiesterase-V inhibitor plus carboplatin . These data provide quantitative measure intratumoral carboplatin level without alteration blood/tumor barrier ( BTB ) permeability vardenafil .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>Patients recurrent malignant glioma metastatic brain cancer require craniotomy gross total resection , subtotal resection biopsy Previously histopathologically proven glioma radiographic appearance metastatic lesion primary neoplasm know metastasize brain Patients must Karnofsky performance status ≥ 60 % ( i.e . patient must able care himself/herself occasional help others ) Patients must normal hematologic , renal liver function ( i.e . Hemoglobin &gt; 10 gm/dl , Absolute neutrophil count ≥ 1500/mm3 , Platelets ≥ 100,000/mm3 , creatinine ≤ 1.5 mg/dl Cr Clearance ≥ 60 mL/min , total bilirubin ≤ 1.5 mg/dl , transaminases ≤ 4 time upper limit institutional normal . Patients must able provide write informed consent Patients serious concurrent infection medical illness , would jeopardize ability patient receive treatment outline protocol reasonable safety Patients pregnant breastfeeding Patients receive concurrent therapy tumor ( i.e . chemotherapeutics investigational agent ) Allergy 5HT ( 3 ) receptor antagonist include tropisetron , ondansetron Patients enzymeinducing anticonvulsant ( Dilantin , Tegretol , Phenobarbital ) Patients unstable angina serious cardiovascular disease Known HIV positivity AIDSrelated illness History allergic reaction platinum compound mannitol Medical condition require use oral nitrate Patients alpha1 adrenergic blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Malignant Glioma</keyword>
	<keyword>Brain Neoplasms , Malignant</keyword>
	<keyword>Brain metastasis</keyword>
</DOC>